Bayer Launches Centafore Imaging Core Lab

Bayer announced the launch of its Imaging Core Lab under the brand name Centafore™. With over 25 years of experience supporting more than 200 clinical trials at Bayer and its arm’s length companies globally, Centafore™ is now positioned as a distinct imaging solution provider, offering tailored services for external customers to support their clinical trials and Software as a Medical Device (SaMD) development across diverse therapeutic areas and development phases. Attendees of the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO) will get the chance to learn more about the Centafore™ team, technology and its services in Chicago from May 30 till June 3 (Booth #24152).

Centafore™ provides technology and services for image management, processing, and interpretation, empowering study sponsors with expert project management and facilitating advanced analyses of imaging data. Its extensive network includes experienced imaging professionals such as board-certified radiologists, enabling customers to effectively manage studies across more than 50 countries.

The services support a wide range of therapeutic areas, including oncology, cardiovascular, central nervous system (CNS), dermatology, women’s health, paediatrics, and digital health. It aims to help pharmaceutical, biotech, medical device and digital health companies with early research through Phase IV trials and SaMD development, and adherence to regulatory and data privacy compliance standards.

As part of Bayer’s ongoing efforts to support global healthcare startups, the Imaging Core Lab Services of Bayer were first presented at ECR 2024. Centafore™ is already collaborating with organizations such as OBIO^® and Luxsonic Technologies to leverage clinical imaging as a critical tool for improving decision-making in clinical trials and software as a medical device development.